CYTOKINETICS, INCORPORATED Effective Income Tax Rate Reconciliation, Tax Credit, Percent
CYTOKINETICS, INCORPORATED (CYTK) reported Effective Income Tax Rate Reconciliation, Tax Credit, Percent of -5.00% for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-27.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits · last filed 2025-02-27
- CYTOKINETICS, INCORPORATED effective income tax rate reconciliation, tax credit, percent for fiscal 2024 was -5.00%.
- CYTOKINETICS, INCORPORATED effective income tax rate reconciliation, tax credit, percent for fiscal 2023 was -4.00%.
- CYTOKINETICS, INCORPORATED effective income tax rate reconciliation, tax credit, percent for fiscal 2022 was -4.00%, a 233.33% decline from fiscal 2021.
- CYTOKINETICS, INCORPORATED effective income tax rate reconciliation, tax credit, percent for fiscal 2021 was 3.00%, a 0.00% change from fiscal 2020.
| Period end | Effective Income Tax Rate Reconciliation, Tax Credit, Percent 12 month | Effective Income Tax Rate Reconciliation, Tax Credit, Percent 12 month as first filed |
|---|---|---|
| 2024-12-31 | -5.00% 10-K · filed 2025-02-27 | |
| 2023-12-31 | -4.00% 10-K · filed 2025-02-27 | 4.00% 10-K · filed 2024-02-28 |
| 2022-12-31 | -4.00% 10-K · filed 2025-02-27 | 4.00% 10-K · filed 2023-03-01 |
| 2021-12-31 | 3.00% 10-K · filed 2024-02-28 | |
| 2020-12-31 | 3.00% 10-K · filed 2023-03-01 | |
| 2019-12-31 | 3.00% 10-K · filed 2022-02-25 | |
| 2018-12-31 | 1.00% 10-K · filed 2021-02-26 | |
| 2017-12-31 | 8.00% 10-K · filed 2019-03-07 | |
| 2016-12-31 | 32.00% 10-K · filed 2018-03-05 | |
| 2015-12-31 | 7.00% 10-K · filed 2018-03-05 | |
| 2014-12-31 | 7.00% 10-K · filed 2017-03-06 | -7.00% 10-K · filed 2015-03-06 |
| 2013-12-31 | 14.00% 10-K · filed 2016-03-03 | -14.00% 10-K · filed 2014-03-07 |
| 2012-12-31 | -19.00% 10-K · filed 2015-03-06 | |
| 2011-12-31 | -1.00% 10-K · filed 2014-03-07 | |
| 2010-12-31 | -4.00% 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |